8-K: Ontrak, Inc. Completes $4 Million Public Offering to Bolster Working Capital

Ontrak, Inc. has successfully closed a public offering raising approximately $3.24 million in net proceeds through the sale of common stock, pre-funded warrants, and common warrants, earmarked for working capital and general corporate purposes.

Summary

• Ontrak, Inc. completed a public offering on June 30, 2025, raising approximately $4 million in gross proceeds.
• The offering included 2,366,665 shares of common stock, 4,300,002 prefunded warrants, and 26,666,668 common warrants.
• Each share of common stock and prefunded warrant was sold with four accompanying common warrants.
• The combined offering price was $0.60 per share of common stock and accompanying warrants, or $0.5999 per pre-funded warrant and accompanying warrants (reflecting a $0.0001 exercise price for pre-funded warrants).
• Net proceeds to the company were approximately $3.24 million after deducting estimated offering expenses and placement agent fees.
• The net proceeds are intended for working capital and general corporate purposes.
• The common warrants have an initial exercise price of $0.60 per share and are exercisable for five years from the date of stockholder approval, which is a condition for their exercisability.
• Prefunded warrants are immediately exercisable at $0.0001 per share and expire when fully exercised.
• Executive officers, directors, and Acuitas Capital LLC entered into six-month lock-up agreements, restricting the disposition of common stock and convertible securities.
• Acuitas Group Holdings, LLC and Acuitas Capital LLC (Acuitas) have agreed to vote in favor of the exercisability of the common warrants, and Acuitas will hold a majority of outstanding common stock immediately before the offering's closing.

Sentiment

Score: 6

Explanation: The offering successfully raised capital for working capital, which is positive for operations. However, the significant number of warrants and their contingent exercisability introduce potential future dilution and uncertainty, balancing the overall sentiment to moderately positive.

Positives

• Successfully raised approximately $3.24 million in net proceeds, providing capital for working capital and general corporate purposes.
• The offering includes pre-funded warrants, allowing for immediate exercise by holders at a nominal price, potentially providing immediate capital inflow.
• Lock-up agreements from key insiders (executive officers, directors, and a significant shareholder) demonstrate commitment and stability for a six-month period post-closing.
• A voting agreement from Acuitas, a majority shareholder, increases the likelihood of obtaining stockholder approval for the exercisability of the common warrants.

Negatives

• The exercisability of the 26,666,668 common warrants is contingent upon obtaining stockholder approval, introducing uncertainty and potential delay for full capital realization from these instruments.
• The offering involves a significant number of warrants (26,666,668 common warrants and 4,300,002 prefunded warrants), which, upon exercise, will lead to substantial dilution for existing shareholders.
• The company is prohibited from effecting or entering into agreements for Variable Rate Transactions for 180 days, limiting certain future financing flexibility.
• The exercise price of the common warrants ($0.60) is subject to downward adjustment for dilutive issuances and stock combination events, potentially leading to further dilution at lower prices, though it has a floor price of $0.19.

Risks

• The exercisability of the common warrants is subject to stockholder approval, and if not obtained, holders will not be able to exercise them, impacting the company's ability to raise additional capital from these instruments.
• Future issuances of common stock or common stock equivalents at prices below the warrant exercise price could trigger anti-dilution adjustments, reducing the warrant exercise price and increasing potential dilution.
• The company is restricted from issuing certain variable rate securities for 180 days, which could limit financing options during this period.
• Hedging activities by purchasers of the securities, including short sales or derivative transactions, could negatively impact the market price of the company's publicly-traded securities.
• Failure to timely deliver warrant shares upon exercise could result in liquidated damages payable by the company to the holder, and potential rescission rights for the holder.
• The company must maintain its listing on the Nasdaq Capital Market and ensure eligibility for electronic transfer through DTC, with potential risks if these conditions are not met.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes. Forward-looking statements indicate expectations regarding the completion of the public offering, the amount of gross proceeds, and the intended use of proceeds, subject to market conditions and closing conditions.

Management Comments

• The company's Chief Financial Officer, James J. Park, signed the 8-K report.
• The company's Chief Executive Officer, Brandon H. LaVerne, signed the Placement Agency Agreement and the Securities Purchase Agreement.

Industry Context

This public offering by Ontrak, Inc., a value-based behavioral healthcare company, reflects a common strategy for growth-oriented companies in the healthcare technology sector to raise capital for operational needs and strategic initiatives. The use of a combination of common stock and warrants is a typical financing structure to attract investors, offering both immediate equity and potential future upside through warrants, while also managing immediate share price impact. The involvement of a placement agent like Roth Capital Partners, LLC is standard for such offerings, providing market access and investor reach.

Comparison to Industry Standards

• The offering structure, combining common stock with warrants, is a common practice in the small-cap and growth-stage healthcare technology sector, often used to make offerings more attractive to investors by providing additional leverage.
• The 7% placement agent fee is within the typical range for 'reasonable best efforts' public offerings of this size, which can vary from 5% to 10% depending on the deal size and complexity.
• The 6-month lock-up period for insiders is standard for public offerings, aiming to provide market stability post-transaction.
• The beneficial ownership limitation (4.99% or 9.99%) in the warrants is a common feature designed to prevent any single holder from triggering beneficial ownership reporting requirements or takeover provisions without prior notice or company consent.
• The anti-dilution provisions and floor price for the warrants are standard protective measures for warrant holders against future dilutive events, while the floor price provides some protection for the company against excessive dilution.

Corporate Governance

Related Party Transactions

• Terren Peizer, Chairman of Acuitas Capital LLC, entered into a lock-up agreement.
• Acuitas Group Holdings, LLC and Acuitas Capital LLC entered into a voting agreement to support the exercisability of the warrants.
• The company entered into the Seventh Amendment to the Keep Well Agreement with Acuitas Capital LLC on June 27, 2025.

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of new shares and potential future dilution from the exercise of warrants. The lock-up agreements and voting agreement from a major shareholder may provide some stability and confidence.
• Investors in the Offering: Will acquire common stock and warrants, with potential for future gains if the stock price increases and warrants become exercisable. They benefit from anti-dilution provisions and the option for cashless exercise.
• Employees: The capital raise provides working capital, which can support ongoing operations and potentially job security, but no direct impact on employee compensation or benefits is mentioned.
• Creditors: The capital raise for working capital may improve the company's liquidity and financial health, potentially reducing credit risk.

Next Steps

• The company will file a final prospectus related to the offering with the SEC.
• The company will apply to list all of the Shares and Warrant Shares on the Nasdaq Capital Market.
• The company will seek stockholder approval for the exercisability of the common warrants.
• The company will continue to file all required reports and documents under the Exchange Act.
• The company will make generally available an earnings statement covering a period of at least 12 consecutive months beginning after the last Closing Date, satisfying Section 11(a) and Rule 158 under the Securities Act.

Key Dates

Recommendation

Keywords

Public Offering, Common Stock, Prefunded Warrants, Common Warrants, Capital Raise, Dilution, SEC Filing, Form 8-K, Corporate Finance, Securities Purchase Agreement, Placement Agency Agreement, Lock-up Agreement, Stockholder Approval, NASDAQ, OTRK, Behavioral Healthcare